Nausea and Vomiting


Varubi Approved for Chemotherapy-Induced Nausea and Vomiting (September 21, 2015)

The United States Food and Drug Administration (FDA) approved the agent Varubi (rolapitant) to be used to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Chemotherapy-induced nausea... Continue Reading

Worried About Nausea? Read This. (November 1, 2010)

Antiemetics help patients avoid a much-feared side effect: chemotherapy-induced nausea and vomiting. By Kari Bohlke, ScD Nausea and vomiting are among the most feared side effects of chemotherapy. Without... Continue Reading

Medical Marijuana in Cancer Care (August 15, 2010)

Does this often controversial substance have a role in supportive care?  Medical marijuana may not have entered mainstream healthcare, but with increasing legalization (14 states have passed medical marijuana... Continue Reading

Coping with Chemotherapy-induced Nausea and Vomiting (February 11, 2010)

Chemotherapy-induced nausea and vomiting (CINV) is a common and serious side effect of cancer treatment. CINV can be severely debilitating and not only interferes with quality of life, but also can result... Continue Reading

Managing Symptoms of Cancer with Complementary Medicine (February 11, 2010)

Cancer treatments like chemotherapy and radiation often have a positive impact on survival, but they can be accompanied by an array of distressing side effects, such as fatigue, depression, nausea, vomiting,... Continue Reading

Study Suggests Long-acting Patch that Prevents Nausea and Vomiting Can Be Given in Combination with Intravenous Medication (February 9, 2010)

Use of a combination of Sancuso® (granisetron transdermal system; a patch that delivers granisetron through the skin for up to five days) and intravenous granisetron appears to be safe and feasible. This... Continue Reading

Cesamet™ Approved for Nausea and Vomiting Associated with Cancer Treatment (May 19, 2006)

The U.S. Food and Drug Administration (FDA) has recently approved the agent Cesamet™ (nabilone) for the treatment of nausea and vomiting in cancer patients undergoing therapy who have not responded to... Continue Reading

Emend® Approved for Prevention of Moderate Chemotherapy-Associated Nausea and Vomiting (January 12, 2006)

The Food and Drug Administration (FDA) recently added another indication to the antinausea drug (antiemetic) Emend® (aprepitant) for patients with cancer undergoing chemotherapy. The new indication includes... Continue Reading

Emend® Controls Vomiting Over Multiple Cycles of Chemotherapy (October 4, 2005)

Among breast cancer patients receiving chemotherapy drugs that are moderately likely to cause vomiting, Emend® (aprepitant) reduced vomiting through four cycles of chemotherapy, according to a study published... Continue Reading

Delayed Nausea After Chemotherapy Poses Treatment Challenge (September 20, 2005)

Neither prochlorperazine nor first-generation 5-HT-receptor antagonists offer sufficient control of delayed chemotherapy-induced nausea, according to a study published in The Lancet Oncology. Chemotherapy... Continue Reading

Emend® Reduces Chemotherapy-Induced Nausea and Vomiting (August 30, 2005)

Emend® Reduces Chemotherapy-Induced Nausea and Vomiting Among cancer patients receiving more than one nausea-inducing chemotherapy drug, the addition of the antiemesis drug Emend® (aprepitant) to standard... Continue Reading

Aloxi™ plus Emend® Highly Effective in Preventing Chemotherapy-Induced Nausea and Vomiting (June 17, 2004)

According to results presented at the 40th annual meeting of the American Society of Clinical Oncology (ASCO), the combination of the anti-emetics Aloxi™ (palonosetron) plus Emend® (aprepitant) is highly... Continue Reading

Addition of Emend® Proven Superior for Prevention of Chemotherapy-Induced Nausea and Vomiting (October 30, 2003)

According to two articles recently published in the Journal of Clinical Oncology, the addition of Emend® (aprepitant) to standard therapy is superior to standard therapy alone for the prevention and/or... Continue Reading

FDA Approves Emend® for Nausea and Vomiting Caused by Chemotherapy (April 27, 2003)

FDA Approves Emend® for Nausea and Vomiting Caused by Chemotherapy The Food and Drug Administration (FDA) recently approved Emend® (aprepitant), in combination with other antiemetics,... Continue Reading

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS